English
Spanish
Italian
French
Greek
Portuguese
Japanese
Danish
Dutch
Finnish
Croatian
Estonian
Filipino
Czech
Korean
Slovenian
Chinese (Simplified)
Chinese (Traditional)
Somali
Hebrew
Polish
Hindi
Hungarian
Slovak
Norwegian
Swedish
Persian
Romanian
Punjabi
Arabic
Ukrainian
Russian
Bulgarian
Indonesian
Bosnian
Afrikaans
Armenian
AlbanianAfter months of anticipation, the first biosimilar version of Humira will become available next week — a pivotal moment in the long-running debate about whether cheaper copies of pricey biologics can lower soaring U.S. health care costs.
For years, Humira dominated the market for treating rheumatoid arthritis and other autoimmune disorders. It became the best-selling medicine in the world and generated billions of dollars in annual sales for AbbVie, which extended its monopoly time and again by filing dozens of patents that made it harder for would-be rivals to launch their own medicines.
Continue to STAT+ to read the full story…
Click this link for the original source of this article.
Author: Ed Silverman
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
